Cyclohexyl acid triazole azines as lpa antagonists

A compound according to Formula (I):

• or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein
• X1, X2, X3, and X4 are each independently CR5 or N;
• provided that no more than two of X1, X2, X3, or X4 are N;
• one of Q1, Q2, and Q3 is NR6, and the other two are N;
• and the dashed circle denotes optional bonds forming an aromatic ring;
• L is a covalent bond or C1-4 alkylene substituted with 0 to 4 R7;
• Z is CHR8a, NR8b or O;
• the Y ring is phenyl or an azine moiety;
• R1 is (—CH2)aR9;
• a is an integer of 0 or 1;
• R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl,
• 4- to 6-membered heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy;
• n is an integer of 0, 1, or 2;
• R3 is halo, cyano, hydroxyl, amino, oxo, —ORa, —SRa, ═S, —NRcRc, ═NH, ═N—OH, ═NRa, ═N—ORa, —NO2, —S(O)2Ra, —S(O)2NHRb, —S(O)2NRcRc, —S(O)2ORb, —OS(O)2Rb, —OS(O)2ORb, —P(O)(ORb)(ORb), —C(O)Rb, C(NRb)Rb, —C(O)ORb, —C(O)NRcRc, —C(NRb)NRcRc, —OC(O)Rb, —NRbC(O)Rb, —OC(O)ORb, —NRbC(O)ORb, —OC(O)NRcRc, NRbC(O)NRcRc, —NRbC(NRb)Rb, —NRbC(NRb)NRcRc, —NH—(C1-3 alkylene)-O-(aryl), C1-6 alkyl, C1-6 deuterated alkyl, C2-6 alkenyl, C1-6 heteroalkyl, 6- to 10-membered aryl, arylalkyl, 5- to 10-membered heteroaryl, heteroarylalkyl, 3- to 8-membered carbocyclyl, carbocyclylalkyl, 4- to 8-membered heterocyclyl, or heterocyclylalkyl;
• wherein the alkyl, heteroalkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, and Ra, by themselves or as part of another group, are each independently substituted with 0 to 5 Rd;
• Ra is selected from the group consisting of C1-6 alkyl, C1-6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, carbocyclyl, carbocyclylalkyl, heterocyclyl, and heterocyclylalkyl;
• Rb is each independently hydrogen or Ra;
• Rc is each independently Rb;
• or alternatively, two Rc, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered heterocyclyl;
• Rd is each independently selected from the group consisting of Ra, alkoxy, haloalkoxy, alkylamino, cycloalkylamino, heterocyclylamino, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkoxy, heterocyclyloxy, haloalkoxy, alkoxyalkoxy, haloalkylamino, alkoxyalkylamino, haloalkoxyalkylamino, arylamino, aralkylamino, aryloxy, aralkyloxy, heteroaryloxy, heteroarylalkyloxy, alkylthio, halo, cyano, hydroxyl, amino, oxo, —ORa, —SRa, ═S, —NRcRc, —NH, ═N—OH, ═NRa, ═N—ORa, —NO2, —S(O)2Ra, —S(O)2NHRb, —S(O)2NRcRc, —S(O)2ORb, —OS(O)2Rb, —OS(O)2ORb, —P(O)(ORb)(ORb), —C(O)Rb, —C(NRb)Rb, —C(O)ORb, —C(O)NRcRc, —C(N)NRcRc, —OC(O)Rb, —NRbC(O)Rb, —OC(O)ORb, —NRbC(O)ORb, —NRbC(O)NRcRc, —NRbC(NRb)Rb, and —NRbC(NRb)NRcRc;
• or alternatively one or two Rd on alkyl, heteroalkyl, aryl, heteroaryl, carbocyclyl, or heterocyclyl, taken together with the atoms to which the Rd is attached, form a cyclic or bridge moiety;
• R4 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl,
• 4- to 6-membered heterocyclyl, 5 or 6-membered heteroaryl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy;
• or R3 and R4, taken together with the atoms to which they are attached, form a monocyclic or bicyclic ring moiety;
• m is an integer of 0, 1, or 2;
• R5 is hydrogen, halo, cyano, hydroxyl, amino, C1-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
• R6 is hydrogen, C1-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
• R7 is halo, oxo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy;
• R8a is hydrogen, halo, hydroxyl, cyano, or C1-4 alkyl;
• R8b is hydrogen or C1-4 alkyl;
• R9 is selected from the group consisting of —CN, —C(O)OR10, —C(O)NR11aR11b,
• Re is C1-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, or haloalkoxyalkyl;
• R10 is hydrogen or C1-10 alkyl;
• and
• R11a and R11b are each independently hydrogen, C1-6 alkyl, C3-6 cycloalkyl, 4- to 6-membered heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy.